David Farquhar
Overview
Explore the profile of David Farquhar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koya E, Golden S, Harvey B, Guez-Barber D, Berkow A, Simmons D, et al.
Nat Neurosci
. 2009 Jul;
12(8):1069-73.
PMID: 19620976
Learned associations between effects of abused drugs and the drug administration environment are important in drug addiction. Histochemical and electrophysiological studies suggest that these associations are encoded in sparsely distributed...
2.
Ghosh S, Auzenne E, Khodadadian M, Farquhar D, Klostergaard J
Bioorg Med Chem Lett
. 2008 Dec;
19(3):1012-7.
PMID: 19097786
Poly-L-glutamic acid (PGA) has previously been demonstrated to be an effective backbone for creating a hydrophilic prodrug of the established anti-tumor agent, paclitaxel, the active agent in Taxol; this approach...
3.
Auzenne E, Ghosh S, Khodadadian M, Rivera B, Farquhar D, Price R, et al.
Neoplasia
. 2007 Jul;
9(6):479-86.
PMID: 17603630
Numerous human tumor types, including ovarian cancer, display a significant expression of the CD44 family of cell surface proteoglycans. To develop tumor-targeted drugs, we have initially evaluated whether the CD44...
4.
Ghosh S, Auzenne E, Farquhar D, Klostergaard J
Bioconjug Chem
. 2007 Apr;
18(3):731-5.
PMID: 17432826
Coumarin derivatives of N,N-dimethylsphingosine (DMSP) were prepared and chemically characterized. They were apparently biologically equivalent to DMSP in terms of tumor cell cytotoxicity and were used to establish the rapid...
5.
Torgov M, Alley S, Cerveny C, Farquhar D, Senter P
Bioconjug Chem
. 2005 May;
16(3):717-21.
PMID: 15898742
The L49 monoclonal antibody against the p97 antigen on melanomas and carcinomas was chemically conjugated to E. coli beta-galactosidase (beta-gal), forming a largely monomeric conjugate with preserved enzymatic activity. The...
6.
Khan S, Kumar S, Farquhar D
Pharm Res
. 2005 Apr;
22(3):390-6.
PMID: 15835744
Purpose: We previously reported the synthesis of bis(pivaloyloxymethyl) 2',3'-dideoxyuridine 5'-monophosphate (POM2-ddUMP) (1a) as a membrane-transport prodrug formulation of the free parent nucleotide, ddUMP. Although successful at delivering ddUMP into cells...
7.
Khan S, Nowak B, Plunkett W, Farquhar D
Biochem Pharmacol
. 2005 Apr;
69(9):1307-13.
PMID: 15826601
Bis(pivaloyloxymethyl) thymidine 5-phosphate (POM(2)-dTMP) has been investigated as a membrane-permeable prodrugs of dTMP. The growth inhibitory activity of POM(2)-TMP has been compared with thymidine (TdR) in wild type CCRF CEM...
8.
Zou Y, Fu H, Ghosh S, Farquhar D, Klostergaard J
Clin Cancer Res
. 2004 Nov;
10(21):7382-91.
PMID: 15534115
Paclitaxel (Taxol) has demonstrated clinical activity in non-small-cell lung cancer (NSCLC), but its use has not led to marked improvements in survival. This ineffectiveness can in part be attributed to...
9.
Farquhar D, Pan B, Sakurai M, Ghosh A, Mullen C, Nelson J
Cancer Chemother Pharmacol
. 2002 Jul;
50(1):65-70.
PMID: 12111114
Purpose: Suicide gene therapy offers the potential to increase the selective toxicity of antitumor agents by intratumoral expression of exogenous enzymes that convert nontoxic prodrugs to toxic products. The use...
10.
Auzenne E, Donato N, Li C, Leroux E, Price R, Farquhar D, et al.
Clin Cancer Res
. 2002 Feb;
8(2):573-81.
PMID: 11839679
Previous preclinical studies with ectopic tumor models have demonstrated remarkable improvements in the therapeutic profile of paclitaxel, formulated as a copolymer with poly-L-glutamic acid, compared with paclitaxel in the clinical...